Provided by Tiger Trade Technology Pte. Ltd.

Trump Concept

3,178.12
-5.2017-0.16%
Number of Gainers:13
Number of Losers:17
Number of Flat:1
PE:- -
High:3,197.04
Open:3,180.76
Low:3,162.90
Close:3,183.32
Volume:109.83M
Turnover:14.25B
Market Cap:6.02T
Float Cap:5.33T

Loading ...

U.S. Stocks on the MOVE-Boeing, Robinhood, Lumentum

Reuters
·
Yesterday

NOTIFICATION OF CHANGE OF THE STOCK BORROW RATE AND FUNDING SPREAD OF THE AFFECTED SECURITIES

GlobeNewswire
·
Yesterday

CTS Eventim AG & Co. KGaA (0EEE) Gets a Buy from J.P. Morgan

TIPRANKS
·
Yesterday

Tesla's Cash Crunch Has Arrived-Blame Its AI Ambitions

Dow Jones
·
Yesterday

Trump Media & Technology Group and Tae Technologies File Form S-4 Registration Statement for Proposed Merger

THOMSON REUTERS
·
Yesterday

Press Release: Trump Media & Technology Group and TAE Technologies File Form S-4 Registration Statement for Proposed Merger

Dow Jones
·
Yesterday

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Yesterday

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Yesterday

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Yesterday

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Yesterday

Merck & Co - no Serious or Opportunistic Infections Observed in Study

THOMSON REUTERS
·
Yesterday

China Aircraft Leasing to Sell Two Boeing 737-800 Jets in Portfolio Trade

TIPRANKS
·
Yesterday

Michael Saylor says Strategy and Strive can grow together

cryptonews
·
Yesterday

KIDZ AI Plans Autonomous Fleet Operations Strategy Tied to Potential 500 Tesla Robotaxi Acquisition

Reuters
·
Yesterday

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Yesterday

SEI Names Connall McGuckian Managing Director, Head of Singapore

Reuters
·
Yesterday

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Yesterday

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Yesterday

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Yesterday

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS
·
Yesterday